Anticoagulation Therapy

Introduction

Anticoagulation therapy is a crucial treatment approach for various medical conditions, with guidelines provided by reputable societies such as the American College of Chest Physicians, American Society of Hematology, and American Heart Association 1, 2, 3

The American College of Chest Physicians recommends a minimum of 3 months for the treatment phase of anticoagulation, with a strong recommendation based on low-certainty evidence 1
The duration of anticoagulation therapy depends on the underlying cause of thrombosis, with 3 months for transient risk factors, 6-12 months for idiopathic thrombosis or mild thrombophilia, and lifelong for high-risk thrombophilia, recurrent thrombotic events, or antiphospholipid syndrome, according to the American Heart Association and American College of Cardiology 3, 4, 5, 6

The standard approach, as recommended by the American Society of Hematology, is to use anticoagulation alone over thrombolysis for most patients 2
Initiate anticoagulation with either intravenous unfractionated heparin or subcutaneous low molecular weight heparin, even in the presence of hemorrhagic changes, as recommended by the American College of Chest Physicians and the American Heart Association 4, 3, 6

The American Heart Association suggests that endovascular interventions may be considered in severe cases with rapid neurological deterioration despite anticoagulation, extensive thrombosis, or poor response to standard therapy 3
Anticoagulation therapy should be initiated immediately for superior sagittal sinus thrombosis, even in the presence of hemorrhagic changes, as the primary treatment approach, according to the American Heart Association 3
The American Society of Hematology recommends anticoagulation for cerebral sinus venous thrombosis in pediatric patients, even with hemorrhage, with a typical duration of 3-6 months depending on risk factors 2

For increased intracranial pressure, antiedematous agents (such as mannitol or hypertonic saline) and consideration of external ventricular drain for hydrocephalus may be necessary, as recommended by the American Association of Neurological Surgeons 7
For seizures, anticonvulsant therapy may be initiated, as approximately 40% of patients develop seizures, according to the American Heart Association 3
Surgical intervention may be considered for significant mass effect from hemorrhagic infarction or evacuation of hematoma in cases of neurological deterioration, as suggested by the American Association of Neurological Surgeons 7

Noncontrast CT of the head is essential in the initial evaluation to assess for hemorrhagic complications and alternative etiologies, although it has limited sensitivity for direct visualization of CST 8
The American College of Radiology recommends CT with CT Venography (CTV) as a useful alternative to MRI when contraindicated or when MRI artifacts are suspected, with a quick examination time of 5-10 minutes, readily available, fewer motion artifacts, and usable with pacemakers or in patients with claustrophobia, and as accurate in diagnosis of CVT as MRV 8

A comparison of CT+CTV and MRI+MRV is as follows:

Imaging Modality	Characteristics
CT+CTV	Quick (5-10 min), readily available, fewer motion artifacts, usable with pacemakers/claustrophobia
MRI+MRV	Better visualization of superficial and deep venous systems, superior detection of early ischemic changes, no radiation exposure, better detection of cortical and deep venous thrombosis, superior detection of micro/macrobleed

Early follow-up CTV or MRV is recommended for patients with persistent or evolving symptoms despite medical treatment, and follow-up imaging at 3-6 months after diagnosis is reasonable to assess recanalization, although the exact timing may vary depending on the clinical context 8

In pregnancy-associated cases, low molecular weight heparin (LMWH) is preferred over unfractionated heparin (UFH), and direct thrombolysis may be considered in severe cases with rapid deterioration, according to the American College of Obstetricians and Gynecologists 3
Non-heparin based anticoagulants should be considered if there is concern for heparin-induced thrombocytopenia, as recommended by the British Medical Journal 9

Despite modern treatment, superior sagittal sinus thrombosis carries significant morbidity, with less than half of patients recovering completely, and poor prognostic factors include female gender, sudden onset, posterior 1/3 occlusion of the superior sagittal sinus, and extension of thrombosis from superior sagittal sinus into cortical veins 3
Mortality rates of approximately 30% have been reported, as stated by the American College of Radiology 10
Hemorrhagic infarction occurs in approximately 40% of cases, and hydrocephalus occurs in approximately 10% of cases, according to the American College of Radiology 10